NCT06477926View on ClinicalTrials.gov

A Study to Assess Relative Bioavailability and Food Effect of ABBV-668 Extended-Release Formulations in Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 9, 2024

Primary Completion Date

September 20, 2024

Study Completion Date

September 20, 2024

Conditions
Healthy Volunteers
Interventions
DRUG

ABBV-668 IR

• Oral Capsule

DRUG

ABBV-668 ER

• Oral Tablets

Trial Locations (1)

60030

Acpru /Id# 266960, Grayslake

Sponsors

Lead Sponsor

AbbVie
All Listed Sponsors
lead

AbbVie

INDUSTRY